URL has been copied successfully!
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Mosquitos are eating us alive into October; I just annihilated an Aedes albopictus that was supping on my shoulder. Is there a Kalshi market for wagers on when dengue will hit SoCal?
The need-to-know this morning
- Novartis is paying $575 million upfront to license an experimental mRNA-based autoimmune therapy from the Chinese firm Abogen Biosciences, the latest case of a large pharma company looking to China to restock its pipeline.
NIH dollars are flowing, but uncertainty persists
The National Institutes of Health spent the $34 billion it was allocated by Congress for research grants in the 2026 fiscal year, but a slower and increasingly opaque funding process is now making it harder to actually do science, a STAT analysis shows.
Please follow us:
